文献速递产科母胎医学

低危妊娠中排除无创产前筛查可检出发现后临床显著拷贝数变异的残留风险

Residual risk for clinically significant copy number variants in low-risk pregnancies, following exclusion of noninvasive prenatal screening-detectable findings.
PubMed 文献 · Am J Obstet Gynecol · 2021-11-08

该研究基于2013至2021年一家大型医院实验室的羊膜穿刺染色体微阵列结果,排除超声异常、母血清筛查异常及多胎妊娠后,计算理论上无创产前筛查正常时临床显著拷贝数变异的残留风险。在7235例妊娠中,临床显著拷贝数变异87例(1.2%),残留风险随无创产前筛查范围扩大而降低,且在高龄孕妇中更高。结论认为该残留风险不可忽视,取决于无创产前筛查范围与孕妇年龄。

要点

  • 7235例低危妊娠中临床显著拷贝数变异87例(1.2%)。
  • 理论无创产前筛查正常后残留风险:3项筛查1.07%(1/94),全基因组筛查0.68%(1/147)。
  • 高龄孕妇残留风险高于<35岁孕妇,范围分别为1.36%–0.82%与0.69%–0.5%。

核心结论

  • 无超声结构异常的妊娠中临床显著拷贝数变异的残留风险不可忽视,且取决于无创产前筛查范围与孕妇年龄。
  • 该信息有助于患者、产科医生和遗传咨询师就产前检测与筛查选择做出知情决策。

研究设计与样本

  • 收集2013至2021年一家大型医院实验室所有接受羊膜穿刺妊娠的染色体微阵列结果。
  • 排除超声异常、母血清筛查异常或多胎妊娠的妊娠。
  • 将临床显著(致病性和可能致病性)拷贝数变异按无创产前筛查可检出范围分类,并计算排除无创产前筛查可检出发现后的理论残留风险。

主要发现

  • 7235例妊娠中,临床显著拷贝数变异87例(1.2%)。
  • 理论无创产前筛查正常后残留风险:3项筛查1.07%(1/94),5项筛查0.78%(1/129),5项筛查含常见微缺失0.74%(1/136),全基因组筛查0.68%(1/147)。
  • 4048例高龄孕妇亚组中,残留风险从3项筛查的1.36%(1/73)到全基因组筛查的0.82%(1/122)。
  • 3187例<35岁孕妇中,残留风险从3项筛查的0.69%(1/145)到全基因组筛查的0.5%(1/199)。

临床怎么用

  • 原文未据此给出推荐,仅指出该知识有助于患者、产科医生和遗传咨询师就产前检测与筛查选择做出知情决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chromosomal microarray analysis detects a clinically significant amount of copy number variants in approximately 1% of low-risk pregnancies. As the constantly growing use of noninvasive prenatal screening has facilitated the detection of chromosomal aberrations, defining the rate of abnormal chromosomal microarray analysis findings following normal noninvasive prenatal screening is of importance for making informed decisions regarding prenatal testing and screening options. OBJECTIVE: To calculate the residual risk for clinically significant copy number variants following theoretically normal noninvasive prenatal screening. STUDY DESIGN: The chromosomal microarray results of all pregnancies undergoing amniocentesis between the years 2013 and 2021 in a large hospital-based laboratory were collected. Pregnancies with sonographic anomalies, abnormal maternal serum screening, or multiple fetuses were excluded. Clinically significant (pathogenic and likely pathogenic) copy number variants were divided into the following: 3-noninvasive prenatal screening-detectable (trisomies 13, 18, and 21), 5- noninvasive prenatal screening-detectable (including sex chromosome aberrations), 5-noninvasive prenatal screening and common microdeletion-detectable (including 1p36.3-1p36.2, 4p16.3-4p16.2, 5p15.3-5p15.1, 15q11.2-15q13.1, and 22q11.2 deletions), and genome-wide noninvasive prenatal screening-detectable (including variants >7 Mb). The theoretical residual risk for clinically significant copy number variants was calculated following the exclusion of noninvasive prenatal screening-detectable findings. RESULTS: Of the 7235 pregnancies, clinically significant copy number variants were demonstrated in 87 cases (1.2%). The residual risk following theoretically normal noninvasive prenatal screening was 1.07% (1/94) for 3-noninvasive prenatal screening, 0.78% (1/129) for 5- noninvasive prenatal screening, 0.74% (1/136) for 5- noninvasive prenatal screening including common microdeletions, and 0.68% (1/147) for genome-wide noninvasive prenatal screening. In the subgroup of 4048 pregnancies with advanced maternal age, the residual risk for clinically significant copy number variants following theoretically normal noninvasive prenatal screening ranged from 1.36% (1/73) for 3- noninvasive prenatal screening to 0.82% (1/122) for genome-wide noninvasive prenatal screening. In 3187 pregnancies of women <35 years, this residual risk ranged from 0.69% (1/145) for 3- noninvasive prenatal screening to 0.5% (1/199) for genome-wide noninvasive prenatal screening. CONCLUSION: The residual risk of clinically significant copy number variants in pregnancies without structural sonographic anomalies is appreciable and depends on the noninvasive prenatal screening extent and maternal age. This knowledge is important for the patients, obstetricians, and genetic counselors to facilitate informed decisions regarding prenatal testing and screening options.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Maya I, Salzer Sheelo L, Brabbing-Goldstein D, et al. Residual risk for clinically significant copy number variants in low-risk pregnancies, following exclusion of noninvasive prenatal screening-detectable findings. Am J Obstet Gynecol. 2021. PMID: 34762861. doi:10.1016/j.ajog.2021.11.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。